Company: MDCXW
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0001062993-25-008246
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 14
---
 Financial Officer that they are designated blacked out employees in respect of a given period prior to the release of financial results which continue until two business days after the time such information has been released to the public and which begin, (i) in the case of interim period financial results, ten business days prior to the end of the fiscal quarter; and (ii) in the case of annual financial results, ten business days before the end of the annual period. From time to time due to specific or anticipated events, we may feel it necessary to issue an unscheduled blackout period for a specific or indefinite period covering insiders or specific employees or groups. In addition, we prohibit our employees, including our named executive officers and the members of our Board, from purchasing any financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds) or otherwise engaging in transactions that are designed to or have the effect of hedging or offsetting any decrease in the market value of the Company's equity securities. Item 11. Executive Compensation. NAMED EXECUTIVE OFFICERS Applicable U.S. and Canadian securities laws require the disclosure of compensation received by each named executive officer of the Company for the two most recently completed financial years. During the financial year ended December 31, 2024, the Company has three named executive officers: Dr. Raza Bokhari (Chief Executive Officer), James Quinlan (Chief Financial Officer) and Dr. Edward Brennan (Chief Scientific Officer & Head of R&D Program). Compensation of our named executive officers generally consists of the following elements: base salaries and participation in our equity incentive plan. The following table sets forth all compensation awarded to, or earned by, our named executive officers for the years ended December 31, 2024 and 2023.

| Name and                                           
 principal position                                 |  Fiscal Year 
        Ended 
 December 31, |  Salary 
     ($) | Share-based 
 Awards      
 ($)         | Option-based 
   Awards ($) | Nonequity    
 incentive    
 plan         
 compensation 
 ($)          | Nonqualified 
 deferred     
 compensation 
 earnings     
 ($)          |    All Other 
 Compensation 
       ($)(1) |        Total 
 Compensation 
          ($) |
| Dr. Raza Bokhari,                                  
 Chief Executive Officer(2)                         |         2024 |       - | -           |      100,856 | -            | -            |            - |      100,856 |
|                                                    |         2023 |       - |